MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
© 1992 Nature Publishing Group
Suggest Documents
Gene therapy for cancer: regulatory considerations for approval.
Stem-cell gene therapy moves toward approval.
Human gene therapy. Approval next time round?
Human gene therapy: anticancer trial's surprise approval.
Erratum to: panobinostat: first global approval.
Erratum to: Durvalumab: First Global Approval.
The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH director.
Palbociclib: first global approval.
Luseogliflozin: first global approval.
Olodaterol: first global approval.
Simeprevir: first global approval.
Finafloxacin: first global approval.
Nintedanib: first global approval.
Blinatumomab: first global approval.
Ataluren: first global approval.
Pembrolizumab: first global approval.
Nemonoxacin: first global approval.
Ceritinib: first global approval.
Vedolizumab: first global approval.
Tofogliflozin: first global approval.
Macitentan: first global approval.
Dinutuximab: first global approval.
Belinostat: first global approval.
Tasimelteon: first global approval.
US company's gene therapy trial is first to bypass RAC for approval.
© 1992 Nature Publishing Group...
149KB Sizes
0 Downloads
0 Views
Download PDF
Recommend Documents
Gene therapy for cancer: regulatory considerations for approval.
Stem-cell gene therapy moves toward approval.
Human gene therapy. Approval next time round?
Human gene therapy: anticancer trial's surprise approval.
Erratum to: panobinostat: first global approval.
Erratum to: Durvalumab: First Global Approval.
The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH director.
Palbociclib: first global approval.
Luseogliflozin: first global approval.
Olodaterol: first global approval.
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms
